Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Sleep apnea affects millions globally, often lurking undetected until it begins impacting overall health. While high blood ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

July 23, 2024 — Nearly 40 million adults in the U.S. have sleep apnea, and more than 30 million of them use a continuous positive airway pressure (CPAP) machine while sleeping. However ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

The global continuous positive airway pressure (CPAP) market is projected to reach a value of USD 900 million by 2033, ...

Sleep apnea, a condition that disrupts breathing during sleep, affects millions of people worldwide, especially adults over ...

There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people with OSA don't sleep well, they are at a higher risk for motor vehicle ...

Researchers, including experts from the University of Missouri School of Medicine, explored the use of senolytics—drugs ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...